文献速递乳腺癌放疗放疗物理与技术

早期乳腺癌5次立体定向部分乳腺照射剂量递增I期试验初步结果

Preliminary Results of a Phase 1 Dose-Escalation Trial for Early-Stage Breast Cancer Using 5-Fraction Stereotactic Body Radiation Therapy for Partial-Breast Irradiation.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-01-12

该I期剂量递增试验评估了早期乳腺癌保乳术后采用机器人立体定向放疗进行5次部分乳腺照射(S-PBI)的耐受性,主要目标是在不超过最大耐受剂量的前提下递增剂量。起始剂量为30 Gy/5次,每队列递增2.5 Gy至40 Gy,共入组75例患者。结果剂量成功递增至40 Gy/5次,仅出现1例剂量限制性毒性,无复发或远处转移,患者和医生评估的美容效果良好。

要点

  • 剂量递增至40 Gy/5次,仅1例剂量限制性毒性,耐受性良好。
  • 中位随访13.5-49.9个月,无复发或远处转移。
  • 医生和患者评估的美容效果优良率高,患者自评术后第一年改善。

核心结论

  • 剂量成功递增至目标剂量40 Gy/5次,仅发生1例剂量限制性毒性。
  • 患者认为术后及立体定向放疗后第一年内美容效果改善。
  • 结果表明毒性轻微且美容效果优良,但需进一步随访。

研究设计与样本

  • I期剂量递增试验,采用机器人立体定向放疗系统对保乳术后瘤床进行5次部分乳腺照射(S-PBI)。
  • 入组标准为导管原位癌或浸润性非小叶上皮组织学、分期0、I或II期、肿瘤大小<3 cm。
  • 起始剂量30 Gy/5次,每队列总剂量递增2.5 Gy至40 Gy。
  • 共入组75例患者,中位年龄62岁。
  • 5个队列的中位随访时间分别为49.9、42.5、25.7、20.3和13.5个月。

主要发现

  • 仅发生3例3级毒性,整个队列中1例剂量限制性毒性。
  • 10例患者出现可触及的脂肪坏死,其中4例有症状。
  • 医生评估美容效果(优良)在基线、6、12、24个月分别为95.9%、100%、96.7%、100%。
  • 患者自评美容效果(优良)在相同时间点分别为86.5%、97.1%、95.1%、95.3%。
  • 医生与患者评估不一致率分别为9.4%、2.9%、1.6%、4.7%。

关键数值与推荐

  • 剂量递增方案:起始30 Gy/5次,每队列递增2.5 Gy至40 Gy。
  • 剂量限制性毒性发生率:整体队列1例。
  • 3级毒性:3例。
  • 可触及脂肪坏死:10例(4例有症状)。

临床怎么用

  • 对于早期乳腺癌保乳术后患者,5次立体定向部分乳腺照射剂量递增至40 Gy显示可接受的毒性和良好的美容效果。
  • 患者自评美容效果在术后第一年改善,但需注意医生与患者评估可能存在不一致。
  • 该方案可行性良好,但需更长期随访以确认疗效和晚期毒性。

局限性

  • 随访时间较短,各队列中位随访13.5至49.9个月。
  • 样本量有限,共75例患者。
  • 需进一步随访以评估长期疗效和毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the tolerability of a dose-escalated 5-fraction stereotactic body radiation therapy for partial-breast irradiation (S-PBI) in treating early-stage breast cancer after partial mastectomy; the primary objective was to escalate dose utilizing a robotic stereotactic radiation system treating the lumpectomy cavity without exceeding the maximum tolerated dose. METHODS AND MATERIALS: Eligible patients included those with ductal carcinoma in situ or invasive nonlobular epithelial histologies and stage 0, I, or II, with tumor size <3 cm. Patients and physicians completed baseline and subsequent cosmesis outcome questionnaires. Starting dose was 30 Gy in 5 fractions and was escalated by 2.5 Gy total for each cohort to 40 Gy. RESULTS: In all, 75 patients were enrolled, with a median age of 62 years. Median follow-up for 5 cohorts was 49.9, 42.5, 25.7, 20.3, and 13.5 months, respectively. Only 3 grade 3 toxicities were experienced. There was 1 dose-limiting toxicity in the overall cohort. Ten patients experienced palpable fat necrosis (4 of which were symptomatic). Physicians scored cosmesis as excellent or good in 95.9%, 100%, 96.7%, and 100% at baseline and 6, 12, and 24 months after S-PBI, whereas patients scored the same periods as 86.5%, 97.1%, 95.1%, and 95.3%, respectively. The disagreement rates between MDs and patients during those periods were 9.4%, 2.9%, 1.6%, and 4.7%, respectively. There have been no recurrences or distant metastases. CONCLUSION: Dose was escalated to the target dose of 40 Gy in 5 fractions, with the occurrence of only 1 dose-limiting toxicity. Patients felt cosmetic results improved within the first year after surgery and stereotactic body radiation therapy. Our results show minimal toxicity with excellent cosmesis; however, further follow-up is warranted in future studies. This study is the first to show the safety, tolerability, feasibility, and cosmesis results of a 5-fraction dose-escalated S-PBI treatment for early-stage breast cancer in the adjuvant setting.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Rahimi A, Thomas K, Spangler A, et al. Preliminary Results of a Phase 1 Dose-Escalation Trial for Early-Stage Breast Cancer Using 5-Fraction Stereotactic Body Radiation Therapy for Partial-Breast Irradiation. Int J Radiat Oncol Biol Phys. 2017. PMID: 28586960. doi:10.1016/j.ijrobp.2017.01.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。